FDA’s Woodcock, other experts highlight persistent issues plaguing pharma, biotech in the wake of Covid-19
WASHINGTON — Current and former government officials proffered a clear-eyed, and often depressing, take Tuesday on the state of clinical trials, the pharmaceutical industry, and